Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin

Leukemia Research

Volumn 22, Issue 7, 1998, Pages 625-629

  Fukushima, Toshihiro ^a   Inoue, Hitoshi ^a   Takemura, Haruyuki ^a   Kishi, Shinzi ^a   Yamauchi, Takahiro ^a   Inai, Kunihiro ^a   Nakayama, Takashi ^a   Imamura, Shin ^a   Urasaki, Yoshimasa ^a   Nakamura, Toru ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Acute myelogenous leukemia; DNA cleavage; Idarubicin; Idarubicinol; Multidrug resistance; Topoisomerase II

Indexed keywords

DAUNORUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); IDARUBICIN; IDARUBICINOL;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DNA CLEAVAGE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL EXTRACTS; CELL SURVIVAL; CYTOTOXINS; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IDARUBICIN; TRYPAN BLUE; TUMOR CELLS, CULTURED;

EID: 0031846588     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00060-5     Document Type: Article

References (28)

1. Arcamone F., Bernardi L., Giardino P., Patelli B., Di Marco A., Casazza A.M., Pratesi G., Reggiani P. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers. Cancer Treat Rep. 60:1976;829.
2. Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., Gulati S., Andreeff M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 77:1991;1666.
3. Fukushima T., Ueda T., Uchida M., Nakamura T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol. 57:1993;121.
4. Fukushima T., Kawai Y., Urasaki Y., Yoshida A., Ueda T., Nakamura T. Influence of idarubicinol on the antileukemic effect of idarubicin. Leukemia Res. 18:1994;943.
5. Berman E., Raymond V., Daghestani A., Arlin Z.A., Gee T.S., Kempin S., Hancock C., Williams L., Stevens Y.-W., Clarkson B.D., Young C. 4-Demethoxydaunorubicin (idarubicin) in combination with 1-β-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Res. 49:1989;477.
6. Carella A.M., Carlier P., Pungolino E., Resegotti L., Liso V., Stasi R., Montillo M., Iacopino P., Mirto S., Pagano L., Leoni F., Martelli F.M., Di Raimondo F., Porcellini A., de Riu L., Nosari A.M., Cimino R., Damasio E., Miraglia E., Fioritoni G., Ricciuti F., Carotenuto M., Longinotti M., Defazio D., Fazi P., Mandelli F. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia. 7:1993;196.
7. Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 79:1992;3267.
8. Urasaki Y, Fukushima T, Ueda T, Iwasaki H, Tsuruo T, Nakamura T. Daunorubicin resistance in a K562-derived cell line and its reversal by idarubicin. In: Miyazaki T, Takaku F, Sakurada K, editors. The Mechanism and New Approach on Drug Resistance of Cancer Cells. Amsterdam: Elsevier Science Publishers, 1993:311.
9. Boiron J.-M., Belloc F., Montastruc M., Cony-Makhoul P., Dumain P., Marit G., Mahon F.-X., Puntous M., Lopez F., Lacombe F., Reiffers J. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia. Leukemia Res. 18:1994;313.
10. Toffoli G., Simone F., Gigante M., Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem Pharmacol. 48:1994;1871.
11. Danks M.K., Schmidt C.A., Cirtain M.C., Suttle D.P., Beck W.T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861.
12. Deffie A.M., Batra J.K., Goldenberg G.J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 49:1989;58.
13. Mirski S.E.L., Evans C.D., Almquist K.C., Slovak M.L., Cole S.P.C. Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res. 53:1993;4866.
14. Fukushima T, Yoshida A, Kawai Y, Urasaki Y, Takauji R, Iwasaki H, Ueda T, Nakamura T. Establishment and characterization of etoposide-resistant human leukemic K562/VP-H2 cell line. In: Proc. Jpn. Cancer Assoc. 53th Annual Meeting, 1994:671 (in Japanese).
15. Moro E., Bellotti V., Jannuzzo M.G., Stegnjaich S., Valzelli G. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydroderivative. J Chromatogr. 247:1983;281.
16. Zhou D.C., Zittoun R., Marie J.P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 9:1995;1661.
17. Poeta G.D., Stasi R., Aronica G., Venditti A., Cox M.C., Bruno A., Buccisano F., Masi M., Tribalto M., Amadori S., Papa G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 87:1996;1997.
18. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 58:1989;351.
19. Speth P.A.J., Minderman H., Haanen C. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol. 16(Suppl. 2):1989;2.
20. Schott B., Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol. 38:1989;4069.
21. Kuffel M.J., Ames M.M. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol. 36:1995;223.
22. Toffoli G., Corona G., Simone F., Gigante M., De Angeli S., Boiocchi M. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines. Int J Cancer. 67:1996;129.
23. Ueda T., Fukushima T. Recent developments with novel anthracyclines for the treatment of haematological malignancies. Exp Opin Invest Drugs. 5:1996;1639.
24. Gieseler F., Biersack H., Brieden T., Manderscheid J., Nubler V. Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Ann Hematol. 69:1994;S13.
25. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650.
26. Simon S.M., Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 91:1994;3497.
27. Lai G.M., Moscow J.A., Alvarez M.G., Fojo A.T., Bates S.E. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer. 49:1991;688.
28. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957.